Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.51 |
| ▸ | AHR | P35869 | 2/20 | 0.51 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020140 | 0.89 | ABL1 (0.59) | CLK4DYRK1ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL3455245 | 0.85 | ABL1 (0.60) | CLK4DYRK1ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13211663 | 0.85 | ABL1 (0.60) | CLK4DYRK1AADORA2AADORA1CYP1A2 | |
| SCHEMBL28315176 | 0.81 | CYP1A2 (0.67) | CLK4DYRK1ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL29712524 | 0.81 | CYP1A2 (0.67) | CLK4DYRK1ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10023268 | 0.80 | ACHE (0.64) | CLK4DYRK1ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL12811023 | 0.80 | ADORA2A (0.57) | CLK4DYRK1ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2876558 | 0.79 | ABL1 (0.63) | CLK4RAB9ASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL5286981 | 0.79 | BRD4 (0.55) | CLK4DYRK1AADORA2AADORA1CYP1A2 | |
| SCHEMBL5849737 | 0.78 | CYP1A1 (0.65) | CLK4DYRK1ASMN1; SMN2TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777407-B2 | Organic light emitting devices comprising a doped triazine electron transport layer | LG DISPLAY CO., LTD. (KR) | 2010-08-17 | — | — | US | disclosed |
| US-20090102373-A1 | Electroluminescent device | HAYOZ PASCAL | 2009-04-23 | — | — | US | disclosed |
| US-20080199726-A1 | Electroluminescent Device | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2008-08-21 | — | — | US | disclosed |
| EP-1743011-A1 | ELECTROLUMINESCENT DEVICE | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-20060251920-A1 | Organic light emitting devices comprising a doped triazine electron transport layer | XEROX CORPORATION | 2006-11-09 | — | — | US | disclosed |
| US-20060251919-A1 | Organic light emitting devices | XEROX CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1597938-A2 | ELECTROLUMINESCENT DEVICE | Ciba SC Holding AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005105950-A1 | ELECTROLUMINESCENT DEVICE | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-6821643-B1 | SATISFACTORY EMISSION IN THE VISIBLE SPECTRUM FROM BLUE TO LONGER WAVELENGTH REGIONS | XEROX CORPORATION | 2004-11-23 | — | — | US | disclosed |
| WO-2004077885-A2 | ELECTROLUMINESCENT DEVICE | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-09-10 | — | — | WO | disclosed |
| US-6225467-B1 | UNIFORM LUMINESCENCE, ELECTROLUMINESCENT EFFICIENCY, DURABILITY, LOW DRIVING VOLTAGE; FOR USE IN FLAT-PANEL EMISSIVE DISPLAY TECHNOLOGIES, INCLUDING TELEVISION SCREENS, COMPUTER SCREENS | XEROX CORPORATION | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090102373-A1 | Electroluminescent device | TAAR5, TYR, TRPC5 | CLK4 1278/4885DYRK1A 2859/4885RAB9A 3537/4885 |
| US-20080199726-A1 | Electroluminescent Device | TPMT, THPO, KYNU | CLK4 3815/4885DYRK1A 3789/4885RAB9A 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.